Aspen says it had a challenging financial year. The pharmaceuticals group has posted a 3% dip in revenue and a 42% decline in headline earnings per share amid high restructuring costs incurred in China, and the impact of a contractual dispute in its manufacturing division. Business Day TV unpacked the performance with Aspen CFO Sean Capazorio.
WATCH: Material contractual dispute weighs on Aspen’s manufacturing unit
Business Day TV speaks to Sean Capazorio, CFO of Aspen
Editor’s Choice
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.